Atlantic Equities

7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%

4 Analysts Takeaways From Johnson & Johnson's Quarterly Results: What Investors Need To Know

Intel Analyst Turns Bearish As Rival AMD Charges Forward

4 Analysts Takeaways From Johnson & Johnson's Quarterly Results: What Investors Need To Know

Intel Analyst Turns Bearish As Rival AMD Charges Forward

Why Snap Analyst Is Confident of Multiple Years Of 'Elevated Growth'

Atlantic Equities Upgrades Snap On Ongoing Solid Trends

Why Snap Analyst Is Confident of Multiple Years Of 'Elevated Growth'

|

Atlantic Equities Upgrades Snap On Ongoing Solid Trends

|

Analyst Sees 'Merit' In Buying Coca-Cola And Pepsi, But Which Stock Has More Upside?

|

Atlantic Equities Upgrades Tiffany Following Big Sell-Off

|

Atlantic Equities Recent News

Electronic Arts' Q2: The Sell-Side's Take

|

Don't Expect A Big Q2 Beat For TJX Companies, Atlantic Equities Says In Downgrade

|

A Peek Into The Markets: U.S. Stock Futures Point To Higher Wall Street Open

|

A Peek Into The Markets: U.S. Stock Futures Rise Ahead Of Earnings, Economic Reports

|

Apple Downgraded As Analyst Foresees A Wave Of New Challenges

|

Southwest Is the 'Best-In-Class' US Airline, In This Analyst's View

|

A Peek Into The Markets: U.S. Stock Futures Up Ahead Of Economic Reports

|

Johnson & Johnson Shares Might Break Lower Before They Break Out

|

EOG Resources The Favorite Energy Play At Atlantic Equities

|

Is The Selloff In Goldman Sachs A Buying Opportunity?

|

A Peek Into The Markets: U.S. Stock Futures Rise Ahead Of Earnings, Economic Data

|

The Bearish First Wave Of Ratings, Price Targets For Snap Post-IPO

|

Snap Says It May Never Become Profitable; Here's Why That's Not Uncommon

|

Wall Street Consensus On Twitter: Sell The Stock

|

Barclays Will Round Out Big Bank Earnings This Week

|

Atlantic Equities Upgrades Apache To Overweight Amid Alpine High Discovery

|

Atlantic Likes Expedia's 'Diversifying Of Earnings Sources,' Upgrades To Overweight

|

Monsanto Shares Have $15-$20 Downside If Bayer Deal Falls Apart

|

3 Things The Market Is Missing About Netflix

|

Atlantic Sets New Neutral Rating On PayPal, Warns Of Long-Term Uncertainty

|

No Longer A Blue Chip? Atlantic Equities Downgrades Disney Amid ESPN Concerns

|

3 Biotechs Atlantic Equities Loves And 1 It's Avoiding

|

Biogen No Longer 'Too Risky,' Atlantic Analyst Sees Massive Upside

|